Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 5, 2007

View Archived Issues

Promising preclinical potential of REP-3123 to treat Clostridium difficile infections

Studies reveal further benefits of quadrivalent papillomavirus vaccination

MF59-adjuvanted H5N1 prepandemic vaccine well tolerated in adults and elderly

Reduction of biomarkers of bone resorption seen with AZD-0530 in cancer patients

AR-709 active against pneumococci, achieves high concentrations in human lungs

Novel fusion protein insulin analogue shows extended action and reduced risk of hypoglycemia

In vitro antiproliferative activity of 17-AAG in uveal melanoma

MRI reveals vascular response to MN-029 in cancer patients

Huya Bioscience licenses antiarrhythmic compound sulcardine

Metabasis HCC therapy assigned orphan medicinal product status in E.U.

CardioVascular BioTherapeutics' wound healing compound successfully completes phase I

Critical Therapeutics advances zileuton injection to phase II

NIH SBIR grant awarded to ISIS for RNAi-based drug discovery

Peptimmune's novel peptide copolymer enters phase I for MS

Tapestry commences phase II clinical evaluation of TPI-287 for advanced pancreatic cancer

Pharmasset commences combination study of R-7128 for HCV treatment

Nanobac gains option to Calgenex technology for atherosclerosis and prostatitis

New oral quinolone antibacterial agent Geninax launched in Japan

FDA accepts BLA for Cinryze and grants priority review

Recent Shionogi patent reports novel agents for cancer pain relief

New agents for inflammatory disorders claimed in recent patents

Once-yearly Aclasta approved in E.U. for postmenopausal osteoporosis

Novel therapeutic agents for neurological disorders disclosed in recent patents

Enzyme replacement therapy Elaprase receives approval in Japan

Recent patents disclose novel antipsychotic, antidepressive and anxiolytic agents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...